PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
PTC Therapeutics's total debt was $536.27M at Sep 30, 2026. For fiscal 2025 it was $286.63M, up 0.4% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $571.72M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.63M | +0.4% |
| FY2024 | Dec 31, 2024 | $285.41M | +0.4% |
| FY2023 | Dec 31, 2023 | $284.21M | -50.3% |
| FY2022 | Dec 31, 2022 | $571.72M | +32.5% |
| FY2021 | Dec 31, 2021 | $431.43M | +39.6% |
| FY2020 | Dec 31, 2020 | $309.15M | -1.5% |
| FY2019 | Dec 31, 2019 | $313.86M | +105.1% |
| FY2018 | Dec 31, 2018 | $153.01M | +5.5% |
| FY2017 | Dec 31, 2017 | $144.97M | +47.6% |
| FY2016 | Dec 31, 2016 | $98.22M | +6.9% |
| FY2015 | Dec 31, 2015 | $91.85M | +187344.9% |
| FY2013 | Dec 31, 2013 | $49.00K | -99.0% |
| FY2012 | Dec 31, 2012 | $4.88M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $536.27M | +87.3% |
| Q2 FY2026 | Jun 30, 2026 | $590.97M | +106.6% |
| Q1 FY2026 | Mar 31, 2026 | $286.94M | +0.4% |
| Q4 FY2025 | Dec 31, 2025 | $286.63M | +0.4% |
| Q3 FY2025 | Sep 30, 2025 | $286.32M | +0.4% |
| Q2 FY2025 | Jun 30, 2025 | $286.01M | +0.4% |
| Q1 FY2025 | Mar 31, 2025 | $285.71M | +0.4% |
| Q4 FY2024 | Dec 31, 2024 | $285.41M | +0.4% |
| Q3 FY2024 | Sep 30, 2024 | $285.11M | -50.3% |
| Q2 FY2024 | Jun 30, 2024 | $284.81M | -50.3% |
| Q1 FY2024 | Mar 31, 2024 | $284.51M | -50.3% |
| Q4 FY2023 | Dec 31, 2023 | $284.21M | -50.3% |
| Q3 FY2023 | Sep 30, 2023 | $573.17M | +102.7% |
| Q2 FY2023 | Jun 30, 2023 | $572.64M | +32.4% |
| Q1 FY2023 | Mar 31, 2023 | $572.09M | +32.5% |
| Q4 FY2022 | Dec 31, 2022 | $571.72M | +32.5% |
| Q3 FY2022 | Sep 30, 2022 | $282.75M | -34.4% |
| Q2 FY2022 | Jun 30, 2022 | $432.37M | +0.4% |
| Q1 FY2022 | Mar 31, 2022 | $431.90M | +0.4% |
| Q4 FY2021 | Dec 31, 2021 | $431.43M | +39.6% |
| Q3 FY2021 | Sep 30, 2021 | $430.96M | +42.2% |
| Q2 FY2021 | Jun 30, 2021 | $430.50M | +36.5% |
| Q1 FY2021 | Mar 31, 2021 | $430.04M | +36.7% |
| Q4 FY2020 | Dec 31, 2020 | $309.15M | -1.5% |
| Q3 FY2020 | Sep 30, 2020 | $302.97M | -3.3% |
| Q2 FY2020 | Jun 30, 2020 | $315.36M | +102.6% |
| Q1 FY2020 | Mar 31, 2020 | $314.57M | +102.8% |
| Q4 FY2019 | Dec 31, 2019 | $313.86M | +105.1% |
| Q3 FY2019 | Sep 30, 2019 | $313.15M | +107.5% |
| Q2 FY2019 | Jun 30, 2019 | $155.68M | +4.6% |
| Q1 FY2019 | Mar 31, 2019 | $155.14M | +5.6% |
| Q4 FY2018 | Dec 31, 2018 | $153.01M | +5.5% |
| Q3 FY2018 | Sep 30, 2018 | $150.93M | +5.5% |
| Q2 FY2018 | Jun 30, 2018 | $148.87M | +5.4% |
| Q1 FY2018 | Mar 31, 2018 | $146.88M | +47.0% |
| Q4 FY2017 | Dec 31, 2017 | $144.97M | +47.6% |
| Q3 FY2017 | Sep 30, 2017 | $143.09M | – |
| Q2 FY2017 | Jun 30, 2017 | $141.24M | – |
| Q1 FY2017 | Mar 31, 2017 | $99.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $98.22M | – |
See a number that looks wrong?